RxDoctor Payments Data

Mark Priola

Family · Prescott, AZNPI 1407161235

Payments from drug & device makers

$2,824in general payments, 2019–2025

Across 136 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$672
  • AstraZeneca$297
  • Novo Nordisk$251
  • GSK$204
  • Exact Sciences$163
  • Lilly USA, LLC$159
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,824 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$179,396
Medicare patients
492
Services billed
2,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$95,761
OzempicSemaglutide53$77,852
FarxigaDapagliflozin Propanediol34$47,603
JardianceEmpagliflozin36$44,986
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$40,282
TrulicityDulaglutide32$34,821
MyrbetriqMirabegron15$19,970
MounjaroTirzepatide18$18,523
XareltoRivaroxaban12$15,470
Tresiba Flextouch U-200Insulin Degludec11$7,241
NovologInsulin Aspart26$6,745
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,549
Levothyroxine Sodium528$4,209
Fentanyl40$4,191
LantusInsulin Glargine,hum.Rec.Anlog25$3,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$95,76168 claims
Novo NordiskOzempic, Novolog$251$84,59779 claims
Lilly USA, LLCTrulicity, Mounjaro$159$53,34550 claims
AstraZenecaFarxiga$297$47,60334 claims
Boehringer IngelheimJardiance$21$44,98636 claims
GSKTrelegy Ellipta$204$40,28242 claims
Astellas Pharma US IncMyrbetriq$90$19,97015 claims
Johnson & JohnsonXarelto$19$15,47012 claims
AbbVieSynthroid, Armour Thyroid$672$4,73389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →